Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by Boston Trust Walden Corp

Boston Trust Walden Corp raised its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 43.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 831,627 shares of the company’s stock after buying an additional 252,089 shares during the quarter. Boston Trust Walden Corp’s holdings in Prestige Consumer Healthcare were worth $64,942,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Millennium Management LLC boosted its stake in Prestige Consumer Healthcare by 565.1% during the 2nd quarter. Millennium Management LLC now owns 101,218 shares of the company’s stock valued at $6,969,000 after purchasing an additional 86,000 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after buying an additional 433 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth approximately $1,095,000. SG Americas Securities LLC acquired a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at approximately $364,000. Finally, Handelsbanken Fonder AB raised its stake in Prestige Consumer Healthcare by 8.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 14,481 shares of the company’s stock valued at $1,044,000 after acquiring an additional 1,100 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $76.74 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market capitalization of $3.79 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. The stock has a fifty day moving average of $79.63 and a 200-day moving average of $75.17. Prestige Consumer Healthcare Inc. has a one year low of $60.00 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.07 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 over the last three months. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PBH shares. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Finally, DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $85.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.